Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,205 | -12,414 | -5,813 | -30,881 | -24,144 |
| Accounts payable and accrued liabilities | -1,195 | -164 | 277 | -2,139 | -1,021 |
| Other Working Capital | -6,215 | -5,288 | -3,909 | -6,646 | -5,709 |
| Other Operating Activity | 3,147 | 1,466 | 375 | 4,264 | 2,625 |
| Operating Cash Flow | $-23,468 | $-16,400 | $-9,070 | $-35,402 | $-28,249 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 53,902 | 27,811 | 23,581 | 46,822 | 46,750 |
| Other Financing Activity | 0 | 0 | 0 | -64 | 0 |
| Financing Cash Flow | $53,902 | $27,811 | $23,581 | $46,758 | $46,750 |
| Beginning Cash Position | 13,986 | 13,986 | 13,986 | 2,630 | 2,630 |
| End Cash Position | 44,420 | 25,397 | 28,497 | 13,986 | 21,131 |
| Net Cash Flow | $30,434 | $11,411 | $14,511 | $11,356 | $18,501 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,468 | -16,400 | -9,070 | -35,402 | -28,249 |
| Free Cash Flow | -23,468 | -16,400 | -9,070 | -35,402 | -28,249 |